- Home
- GLTO vs CVV Comparison
GLTO vs CVV Comparison
Compare GLTO & CVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- CVV
- Stock Information
- Founded
- GLTO 2011
- CVV 1982
- Country
- GLTO Denmark
- CVV United States
- Employees
- GLTO N/A
- CVV N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- CVV Industrial Machinery/Components
- Sector
- GLTO Health Care
- CVV Technology
- Exchange
- GLTO Nasdaq
- CVV Nasdaq
- Market Cap
- GLTO 23.7M
- CVV 23.1M
- IPO Year
- GLTO 2020
- CVV N/A
- Fundamental
- Price
- GLTO $10.99
- CVV $3.88
- Analyst Decision
- GLTO Buy
- CVV
- Analyst Count
- GLTO 1
- CVV 0
- Target Price
- GLTO $10.00
- CVV N/A
- AVG Volume (30 Days)
- GLTO 7.6M
- CVV 52.3K
- Earning Date
- GLTO 10-31-2025
- CVV 11-12-2025
- Dividend Yield
- GLTO N/A
- CVV N/A
- EPS Growth
- GLTO N/A
- CVV N/A
- EPS
- GLTO N/A
- CVV N/A
- Revenue
- GLTO N/A
- CVV $29,036,000.00
- Revenue This Year
- GLTO N/A
- CVV N/A
- Revenue Next Year
- GLTO N/A
- CVV N/A
- P/E Ratio
- GLTO N/A
- CVV N/A
- Revenue Growth
- GLTO N/A
- CVV 34.35
- 52 Week Low
- GLTO $2.01
- CVV $2.46
- 52 Week High
- GLTO $31.70
- CVV $4.80
- Technical
- Relative Strength Index (RSI)
- GLTO 58.62
- CVV 61.20
- Support Level
- GLTO $10.53
- CVV $3.23
- Resistance Level
- GLTO $18.45
- CVV $4.31
- Average True Range (ATR)
- GLTO 2.35
- CVV 0.27
- MACD
- GLTO 0.43
- CVV 0.07
- Stochastic Oscillator
- GLTO 26.56
- CVV 61.26
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About CVV CVD Equipment Corporation
CVD Equipment Corp is engaged in the manufacturing of chemical vapor deposition equipment, customized gas control systems, the manufacturing of process equipment suitable for the synthesis of a variety of one-dimensional nanostructures and nanomaterials and a line of furnaces, all of which are used to produce semiconductors and other electronic components. The company operates through the segments of CVD Equipment, CVD materials, and Stainless Design Concepts, MesoScribe. It generates maximum revenue from the CVD Equipment segment. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport, and similar equipment. Company operates in USA, North America, Europe, Middle East and Africa, and Asia-Pacific.